Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.
Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.
Fate Therapeutics reported encouraging advancements in its clinical trials for its iPSC-derived NK cell therapies. The Phase 1 study of FT596 has expanded, treating patients with B-cell lymphoma and now chronic lymphocytic leukemia. Initial patients have also been treated with FT516 in combination with avelumab for solid tumors. The company has initiated enrollment for FT538, a CRISPR-edited therapy, targeting acute myeloid leukemia and multiple myeloma. Financially, total revenue for Q3 2020 was $7.6 million, while R&D and G&A expenses were $30.7 million and $8.4 million, respectively.
Fate Therapeutics (NASDAQ: FATE) announced the acceptance of four oral presentations at the 62nd American Society of Hematology Annual Meeting, to be held virtually from December 5-8, 2020. These presentations will focus on the company’s iPSC-derived NK cell therapies, particularly FT596, in clinical trials for B-cell lymphoma. Additionally, an investor event titled "The Power of hnCD16" is scheduled for December 4, showcasing the functionality of the hnCD16 Fc receptor, which enhances tumor-targeting capabilities. The company aims to develop scalable, off-the-shelf cancer immunotherapies.
Fate Therapeutics, Inc. (NASDAQ: FATE) will host a conference call on November 5, 2020, at 5:00 p.m. ET to discuss its third quarter 2020 financial results and provide a corporate update.
Participants can join by calling (877) 303-6235 domestically or (631) 291-4837 internationally using conference ID 1060606.
The live audio webcast will be accessible via the company's website, with an archived version available two hours post-event.
Fate Therapeutics (NASDAQ: FATE) announced that five abstracts for its iPSC product platform will be presented at the upcoming SITC annual meeting from November 9-14, 2020. The abstracts highlight clinical data from 15 patients in the Phase 1 trial of FT500 for advanced solid tumors. This includes a dose-expansion stage for patients with non-small cell lung cancer or Hodgkin lymphoma. The presentation topics include targeting tumor antigens and the efficacy of iPSC-derived NK cell immunotherapy. Fate's iPSC platform aims to create effective, off-the-shelf therapies, supported by a robust patent portfolio.
Fate Therapeutics (NASDAQ: FATE) announced its participation in the Jefferies Cell Therapy Virtual Summit on October 6, 2020, at 2:30 p.m. E.T.. The management will engage in a fireside chat to discuss advancements in their programmed cellular immunotherapies for cancer and immune disorders. A live webcast of the presentation will be accessible via the company's investor relations webpage. Fate Therapeutics is known for its innovative iPSC product platform, developing both cancer immunotherapies and treatments for immune disorders.
Fate Therapeutics (NASDAQ: FATE) announced its participation in several investor conferences scheduled for September 2020, including the Baird Global Healthcare Conference and the Citi 15th Annual BioPharma Conference. The company, known for its innovative cellular immunotherapies for cancer and immune disorders, is set to present at multiple venues over the course of the month. Interested investors can access live webcasts on the company’s investor relations website, with archived replays available shortly thereafter.
Fate Therapeutics reported encouraging early clinical data for its FT596 product in a patient with refractory diffuse large B-cell lymphoma, showing a partial response with significant tumor size reduction and no serious side effects. The company has cleared multiple IND applications for its innovative iPSC-derived therapies, including FT538 for AML and FT819 for B-cell leukemias, and continues to advance its collaboration with Janssen to develop CAR NK and CAR T-cell therapies. As of June 30, 2020, Fate Therapeutics had $533 million in cash and investment resources.
Fate Therapeutics (NASDAQ: FATE) announced that its Chief Scientific Officer, Dan Shoemaker, Ph.D., will present at the Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 11:30 a.m. EST. A live webcast will be available on the company's investor relations website, with an archived replay to follow.
The company focuses on developing programmed cellular immunotherapies for cancer and immune disorders, utilizing its proprietary induced pluripotent stem cell (iPSC) platform.
Fate Therapeutics has entered an exclusive license agreement with Baylor College of Medicine for alloimmune defense receptors, a revolutionary technology aimed at preventing immune rejection of allogeneic cell therapies. Recent preclinical data published in Nature Biotechnology demonstrates that engineered allogeneic CAR T cells equipped with these receptors successfully evade immune rejection and achieve long-lasting tumor eradication. This innovation could potentially address significant challenges in allogeneic therapies, enhancing their effectiveness while preserving the patient’s immune system.
Fate Therapeutics announced the closing of a public offering of 7,108,796 shares at $28.31 each, raising approximately $201.3 million. The offering included 927,324 shares from underwriters' options. Funds will support clinical trials, production of clinical candidates, and expansion of manufacturing operations. Additionally, the company plans to sell 1,766,160 shares to Johnson & Johnson Innovation for about $50 million. This move aligns with Fate's focus on developing advanced cellular immunotherapies.